Venous thromboembolism
Jun 1, 2025, 03:33
Blood Advances Study Reveals Misclassification of Venous Thromboembolism (VTE) Risk
American Society of Hematology shared a post on X:
“Venous thromboembolism (VTE) affects 1 million Americans yearly. A recent study in Blood Advances shows 1 in 3 medical patients had misclassified VTE risk, leading to inappropriate treatment for half. ”
Accurate VTE risk assessment is essential to avoid both under- and overtreatment. This study draws attention to how often patients are misclassified.
Check out the full study here.
Get the latest news on Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25